Columbus BioTech, Clarametyx Biosciences, raises $33 million Series A

Clarametyx Biosciences, a Columbus-based BioTech startup, has raised a $33 million Series A round to advance its cutting-edge anti-biofilm biologics for combating serious bacterial infections.

The company, founded in 2020, specializes in developing targeted, immune-empowering biologic therapies to address persistent infections linked to biofilms.

Also announced was a partnership with the Cystic Fibrosis Foundation. Clarametyx will conduct clinical studies targeting cystic fibrosis-associated infections, a move that aligns with the company's mission to address critical unmet needs in infectious disease management. CF will invest up to $5 million in Clarametyx.

Investors in the Series A round include: the Ohio Innovation Fund (lead), Nationwide Children’s Hospital, Rev1 Ventures, JobsOhio Growth Capital, C Bio Investors, and 1776 Fund.

Why this matters to Ohio

Ohio is a global leader in healthcare and a hub for cutting-edge medical and life science innovation, research, and patient care.

This is the latest success story for Ohio BioTech and life science and a $33 million Series A is a big number that continues to put Ohio startups on the map. Many of the investors in Clarametyx are located in Ohio - including the round’s lead, the Ohio Innovation Fund.

And the technology was built in Ohio. Clarametyx is a spin out from Nationwide Children's Hospital in Columbus.

What they're saying

“We graciously welcome our new investors and appreciate the continued commitment of our existing investors. This successful raise enables us to expand our clinical evaluations of a platform that we believe will address critical unmet needs in infectious disease management. We are especially grateful for the support of the Cystic Fibrosis Foundation to evaluate this technology’s promise to improve the lives of people with cystic fibrosis, a population particularly vulnerable to persistent bacterial infections. We believe this research will further support the broad applicability of this first-in-class technology.”

- David Richards, CEO of Clarametyx Biosciences

“Global health authorities continue to raise alarms about persistent bacterial infections and the rise in antimicrobial resistance associated with overuse of antibiotics. There is a clear and urgent need for novel technologies that can enhance the effectiveness of today’s antibiotics to address these challenging infections, and the Clarametyx technology represents a compelling strategy that we can propel into broader clinical studies to serve this need.”

- William Baumel, Managing Director of the Ohio Innovation Fund